Recent Updates
Recently added Catalysts
TNDM Positive Sentiment

Tandem Diabetes Care Announces Upcoming Conference Presentation

Tuesday, July 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Tandem Diabetes Care, Inc. has announced its participation in Canaccord Genuity's 46th Annual Growth Conference, scheduled for August 11, 2026. The management will provide a company update during the presentation, which will be available via live webcast and archived for 30 days. This engagement highlights the company's commitment to transparency and investor relations.
Price reaction · baseline $17.76 (2026-07-28 close) · hit after-hours · clean, no other TNDM news in the window
day 0 close · peak
+4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Tandem Diabetes Care is actively engaging with investors.
  • The company is providing updates on its progress.
  • The presentation will be accessible to a wide audience via webcast.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at Canaccord Genuity’s 46th Annual Growth Conference on Tuesday, August 11, 2026 at 1:30pm Eastern Time (10:30am Pacific Time). The presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care

Frequently Asked Questions

When is Tandem Diabetes Care's conference presentation?

The presentation is scheduled for August 11, 2026, at 1:30 PM Eastern Time.

How can I access the conference presentation?

The presentation will be webcast live and archived for 30 days.

What is the purpose of the presentation?

Management will provide a company update during the presentation.

Where is the conference taking place?

The conference is hosted by Canaccord Genuity.

ShareAdd on Google
Tags: TNDM Tandem Diabetes Care Canaccord Genuity diabetes technology insulin delivery
Last updated: Jul 28, 2026

Biotech snapshot

Cash runway
$456M liquidity · $12M/mo burn
~38 mo
Minimal dilution risk